To learn more about the Sponsor of this trial, Zai Lab, click here.
ABOUT PLAQUE PSORIASIS
Psoriasis is a common skin condition that affects 2–3% of the population worldwide, reaching upwards of 8–11% in some Northern European countries1. Psoriasis comes in many forms, though plaque psoriasis is the most common2. Around 80-90% of people living with psoriasis experience plaque psoriasis. Plaque psoriasis affects all ethnicities, though can appear differently on different skin tones. On lighter, pale skin, the plaques can appear as raised, red patches covered with a white or grey buildup of dead skin cells. On darker skin, these plaques may appear darker, thicker, and hold a more purple/dark brown appearance3.
Plaque Psoriasis is commonly treated using topical treatments (applied on the skin), light therapy, oral medications, or injectable medications. Some of these medications can include steroids, Vitamin D, and retinoids. Not every person with plaque psoriasis responds the same way to different treatment options. New treatments are being researched and studied today. Exploring these new possible treatments through clinical trials is an important way to find new options for participants with plaque psoriasis.
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716585/
2. https://www1.racgp.org.au/ajgp/2020/july/the-multiple-comorbidities-of-psoriasis
3. https://www.psoriasis.org/plaque/
About the Clinical Trial
If you or a loved one has been diagnosed with plaque psoriasis, you or they may be eligible to participate in a new clinical trial. The purpose of this trial is to determine if a new investigational topical treatment called ZL-1102 is safe and effective in treating plaque psoriasis. Approximately 250 participants will be recruited into this clinical trial. Participants who enroll will be asked to participate for up to 24 weeks including screening, treatment, and follow up periods. During this 24-week time frame, participants will also be asked to visit the clinical trial site approximately 8 times.
Participants who successfully enroll will be assigned by random chance to receive ZL-1102 gel or placebo gel during the clinical trial. The placebo looks like the active investigational drug ZL-1102, though it does not contain any active drug and cannot provide any treatment benefit. During the clinical trial, ZL-1102 or placebo will be applied to the affected skin areas once or twice a day, everyday, everyday for 16 weeks.
If you live in Australia, click here to see if you pre-qualify
Clinical Trial Criteria
To participate in this clinical trial, participants must*:
- Be 18 years of age or older
- Be clinically diagnosed with plaque psoriasis, and have had plaque psoriasis for at least 6 months
- Agree to NOT have prolonged sun exposure during the clinical trial period (no tanning beds, no extended outside activities in direct sunlight)
- Be eligible for topical treatment only (does not require additional treatment such as injections)
Other criteria for eligibility apply. Clinical trial participants receive trial-related medical exams
and investigational drug at no cost. Compensation for time and travel may be available.*